Wall Street Zen Downgrades Vanda Pharmaceuticals (NASDAQ:VNDA) to Sell

Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

VNDA has been the subject of several other research reports. B. Riley Financial boosted their price target on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, December 31st. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 5th. Zacks Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, January 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Vanda Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $13.63.

Vanda Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ VNDA opened at $6.09 on Friday. The company has a quick ratio of 2.38, a current ratio of 2.39 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $7.35 and its two-hundred day moving average is $5.70. Vanda Pharmaceuticals has a 52-week low of $3.81 and a 52-week high of $9.60. The firm has a market cap of $359.98 million, a price-to-earnings ratio of -1.63 and a beta of 0.62.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.18) by ($0.21). The business had revenue of $57.22 million for the quarter, compared to analyst estimates of $59.28 million. Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%. Research analysts predict that Vanda Pharmaceuticals will post -1.12 EPS for the current year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Torren Management LLC purchased a new stake in shares of Vanda Pharmaceuticals in the 4th quarter valued at about $25,000. Bailard Inc. increased its position in Vanda Pharmaceuticals by 16.2% during the second quarter. Bailard Inc. now owns 26,100 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 3,631 shares during the period. Jane Street Group LLC lifted its stake in Vanda Pharmaceuticals by 6.1% in the second quarter. Jane Street Group LLC now owns 79,107 shares of the biopharmaceutical company’s stock valued at $373,000 after buying an additional 4,533 shares during the last quarter. Savant Capital LLC raised its position in Vanda Pharmaceuticals by 30.3% in the 3rd quarter. Savant Capital LLC now owns 22,493 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 5,229 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in Vanda Pharmaceuticals by 456.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 5,328 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Key Stories Impacting Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Zacks Research upgraded Vanda from a “hold” to a “strong‑buy,” which could attract buying interest from momentum and value‑oriented investors. Zacks/TickerReport Upgrade
• Neutral Sentiment: Company released its Q4 and full‑year 2025 financial results and an earnings call recap showing revenue growth but widening losses; this is the baseline data investors will parse for guidance and runway. Vanda Q4 & FY2025 Results (Press Release)
• Negative Sentiment: Q4 results missed expectations: EPS came in as a larger loss and revenue slightly trailed estimates, which prompted the stock reaction and investor uncertainty. Vanda: Q4 Earnings Snapshot
• Negative Sentiment: Vanda lowered FY‑2026 revenue guidance to roughly $230M–$260M versus a consensus near $273M, signaling slower near‑term growth and pressuring valuation and cash‑flow expectations. Guidance in Vanda Q4 Press Release
• Negative Sentiment: Regulatory uncertainty: analysts and commentary highlight meaningful FDA approval risk for Bysanti and imsidolimab, which raises binary event risk and could delay or reduce future revenues. TipRanks: Regulatory Hurdles for Bysanti and Imsidolimab
• Negative Sentiment: Investor legal risk: a Pomerantz LLP investigation into Vanda has been announced, which can increase near‑term sell pressure and legal costs if a suit proceeds. Pomerantz Investor Alert

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.